| Literature DB >> 33811813 |
Andreas H Groll1, Dorothea Pana2, Fanny Lanternier3, Alessio Mesini4, Roland A Ammann5, Dina Averbuch6, Elio Castagnola4, Simone Cesaro7, Dan Engelhard6, Carolina Garcia-Vidal8, Jukka Kanerva9, Nicole Ritz10, Emmanuel Roilides11, Jan Styczynski12, Adilia Warris13, Thomas Lehrnbecher14.
Abstract
Paediatric patients with cancer and those undergoing allogeneic haematopoietic cell transplantation have an increased susceptibility to invasive fungal diseases. In addition to differences in underlying conditions and comorbidities relative to adults, invasive fungal diseases in infants, children, and adolescents are unique in terms of their epidemiology, the validity of current diagnostic methods, the pharmacology and dosing of antifungal agents, and the absence of phase 3 clinical trials to provide data to guide evidence-based interventions. To re-examine the state of knowledge and to further improve invasive fungal disease diagnosis, prevention, and management, the 8th European Conference on Infections in Leukaemia (ECIL-8) reconvened a Paediatric Group to review the literature and to formulate updated recommendations according to the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and European Confederation of Medical Mycology (ECMM) grading system, which are summarised in this Review.Entities:
Year: 2021 PMID: 33811813 DOI: 10.1016/S1470-2045(20)30723-3
Source DB: PubMed Journal: Lancet Oncol ISSN: 1470-2045 Impact factor: 41.316